Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization Program.

Authors

Mark H Rozenbaum, Ahuva Averin, Derek Weycker, Rotem Lapidot, Amanda Miles, Maria J Tort, Paula Peyrani, Jeffrey Vietri, Alexander Lonshteyn, Stephen I Pelton

Published in

Open forum infectious diseases. Volume 13. Issue 9. Pages ofag528. Epub Aug 24, 2026.

Abstract

Use of 13-valent pneumococcal conjugate vaccine (PCV13) has reduced the burden of pneumococcal disease among both children and adults. Research has indicated that some population subgroups have benefited more than others. This study estimated rates of inpatient all-cause pneumonia among US adults by age, race, comorbidity profile, and household income (HHI), before and after universal recommendation for PCV13 in children and targeted recommendation for use in adults.
A retrospective observational study was conducted using Optum's de-identified Clinformatics Data Mart Database (2007-2019). Adults aged ≥18 years were stratified by age, race, comorbidity profile (low-risk, at-risk/high-risk), and annual household income. Inpatient all-cause pneumonia episodes were identified via relevant International Classification of Diseases (Ninth and Tenth Revisions) codes. Rates per 100 000 person-years and incidence rate ratios (IRRs) were calculated for the pre-PCV13 (2008-2009), peri-PCV13 (2010-2012), post-PCV13#1 (2013-2016), and post-PCV13#2 (2017-2019) periods.
Among 38.7 million US adults, inpatient all-cause pneumonia rates decreased from the pre-PCV13 to post-PCV13#2 period among all age groups (eg, 72.9 to 38.2 among 18- to 49-year-olds and 1621.8 to 1326.0 among ≥75-year-olds). Irrespective of age, rates generally decreased from the pre-PCV13 to post-PCV13#2 period within subgroups defined by race, comorbidity profile, and HHI; the greatest relative reductions were observed among persons aged 18-49 years. During the post-PCV13#2 period, the highest rates of inpatient all-cause pneumonia persisted in Black adults, at-risk/high-risk adults, and adults with HHI <$100 000.
Despite reductions in inpatient all-cause pneumonia following pediatric PCV13 introduction, residual disparities persist for Black, at-risk/high-risk, and low- and middle-income adults. Strategies to reduce persistent disparities in disease burden among affected adults should be considered and implemented.

PMID:
42703612
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.